KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Twist Bioscience (TWST) EBT Margin (2017 - 2025)

Twist Bioscience (TWST) has disclosed EBT Margin for 6 consecutive years, with 4646500.0% as the latest value for Q3 2023.

  • On a quarterly basis, EBT Margin rose 464658869.0% to 4646500.0% in Q3 2023 year-over-year; TTM through Sep 2023 was 114.2%, a 206.0% decrease, with the full-year FY2024 number at 717813.79%, down 335150621.0% from a year prior.
  • EBT Margin was 4646500.0% for Q3 2023 at Twist Bioscience, up from 89.07% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 4646500.0% in Q3 2023 to a low of 323.94% in Q4 2019.
  • A 5-year average of 244422.22% and a median of 121.12% in 2021 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: plummeted -12732bps in 2019, then soared 464658869bps in 2023.
  • Twist Bioscience's EBT Margin stood at 323.94% in 2019, then surged by 64bps to 116.66% in 2020, then dropped by -14bps to 133.2% in 2021, then surged by 42bps to 76.96% in 2022, then soared by 6037278bps to 4646500.0% in 2023.
  • Per Business Quant, the three most recent readings for TWST's EBT Margin are 4646500.0% (Q3 2023), 89.07% (Q2 2023), and 97.18% (Q1 2023).